/

Società

An

Non verificato

Anokion SA

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

3 comunicati stampa

Guarda tutti i comunicati

08/01/2025

Industria

Salute

Medicina - Varie

Scienza

Farmaceutica

Biotecnologia

Anokion Announces Positive Symptom Data from its Phase 2 Trial Evaluating KAN-101 for the Treatment of Celiac Disease

Fonte

Emittente

1.00

0

19/12/2024

Industria

Biotecnologia

Farmaceutica

Salute

Medicina - Varie

Anokion Announces the Early Completion of Enrollment in the ACeD-it Phase 2 and the SynCeD Phase 2a Trials of KAN-101 for the Treatment of Celiac Disease

Fonte

Emittente

1.00

0

18/09/2024

Eventi

Fiere

Industria

Salute

Medicina - Varie

Scienza

Farmaceutica

Biotecnologia

Anokion Announces New Data from the Phase 1 MoveS-it Study Supporting ANK-700 as a Novel, Potential Disease Modifying Treatment for Relapsing-Remitting Multiple Sclerosis

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0